The NDA submission timeline (Q2 2026 completion) is the primary catalyst — approval would unlock first-to-market status in STGD1. Monitor FDA acceptance and any PDUFA date assignment. The cash runway ($798.6M) funds operations for years, reducing dilution risk. The EPS miss is secondary to the regulatory milestone.
Price Chart
Executive Summary
Belite Bio reported Q1 2026 GAAP EPS of -$0.68, missing the -$0.64 consensus by 6.3%, with net loss widening to $26.9M from $14.3M a year ago. The key catalyst is the rolling NDA submission for tinlarebant in Stargardt disease, expected to complete in Q2 2026, alongside a strong cash position of $798.6M. The EPS miss and rising R&D/SG&A expenses are offset by the NDA milestone and pre-commercialization progress.
Key Financial Metrics
Key Facts
- GAAP EPS -$0.68 vs consensus -$0.64 (6.3% miss)
- Net loss $26.9M vs $14.3M YoY, driven by R&D ($15.7M, +67%) and SG&A ($17.0M, +178%) increases
- Cash & equivalents $276.4M plus $522.2M in U.S. treasuries = $798.6M total liquidity
- Rolling NDA submission for tinlarebant in STGD1 initiated April 2026, completion expected Q2 2026
- DRAGON II Phase 2/3 trial enrollment completed with 73 subjects (target 60)
- PHOENIX Phase 3 GA trial enrollment completed with 530 subjects; interim analysis expected
- All key commercial leadership positions hired for STGD1 launch preparation
Financial Impact
EPS miss of $0.04 vs consensus; operating cash burn ~$76.5M/year; NDA catalyst could drive significant re-rating if approved
Risk Factors
- FDA may issue a Complete Response Letter (CRL) if NDA data package is insufficient
- Rising operating expenses ($32.7M/quarter) could accelerate cash burn if NDA review extends
- Competing therapies for STGD1/GA could emerge before commercialization
- Stock has high beta to binary regulatory events — significant downside risk on negative FDA decision
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298259 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $147.34 | awaiting T+20 | — | $147.33 (−0.01%) |
Sep 9, 2026 6w ago | Insider Cluster | $175.07 $152.52 | ▲ +12.88% | ▲ +15.01% | $147.33 (+15.85%) |
Aug 12, 2026 10w ago | 6-K | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Aug 12, 2026 10w ago | Press Release | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Jun 12, 2026 19w ago | 6-K | $144.24 $147.03 | ▲ +1.93% | ▲ +2.68% | $147.33 (+2.14%) |
May 20, 2026 22w ago | Press Release | $143.36 $146.12 | ▲ +1.93% | ▲ +1.18% | $147.33 (+2.77%) |
Apr 21, 2026 26w ago | 6-K | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 21, 2026 26w ago | Press Release | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers